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Vascular smooth muscle cell (VSMC) proliferation
is the major pathologic feature associated with
chronic allograft nephropathy, and mycophenolic acid
(MPA) inhibits VSMC proliferation. Since the role
of inosine monophosphate dehydrogenase (IMPDH)-
dependent de novo guanosine synthesis is limited in
VSMCs, we examined the effects of MPA on platelet-
derived growth factor (PDGF)-induced cellular ROS
and mitogen-actived protein kinases (MAPK) activa-
tion in VSMCs. Primary cultured rat VSMCs were stim-
ulated with PDGF-BB in the presence or absence of
MPA. Cell proliferation was assessed by [3H]-thymidine
incorporation, ROS by flow cytometry and MAPK ac-
tivation by Western blot analysis. PDGF increased cell
proliferation, cellular ROS and extracellular-regulated
protein kinase (ERK) 1/2 and p38 MAPK activation by
3.4-, 1.6-, 3.3- and 3.9-fold, respectively. MPA at above
1 lM inhibited PDGF-induced cellular ROS and ERK
1/2 and p38 MAPK activation, as well as prolifera-
tion. Structurally different anti-oxidants and inhibitor
of ERK or p38 MAPK blocked PDGF-induced prolifer-
ation. Anti-oxidants also inhibited ERK 1/2 and p38
MAPK activation. Exogenous guanosine partially re-
covered the inhibitory effect of MPA on VSMC prolif-
eration. These results suggest that MPA may inhibit
PDGF-induced VSMC proliferation partially through
inhibiting cellular ROS, and subsequent ERK 1/2
and p38 MAPK activation in addition to inhibiting
IMPDH.
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Introduction
Despite improvements in the short-term success of kidney
transplantation during recent years, the rate of long-term
graft attrition remains high. Abnormal vascular remodeling
has been proposed to be the major pathogenesis of chronic
allograft dysfunction. The final events of vascular diseases
such as chronic allograft vasculopathy (1–4), atherosclero-
sis (5) and restenosis (6) include the serial events of vas-
cular smooth muscle cell (VSMC) proliferation, migration
and accumulation of extracellular matrix. Immunologic or
non-immunologic injury of the endothelium and the sub-
sequent vascular response may initiate the release of cy-
tokines and growth factors and lead to the aforementioned
serial events of VSMCs.
Mycophenolic acid (MPA), a selective and uncompetitive
inosine monophosphate dehydrogenase (IMPDH) inhibitor,
inhibits not only lymphocyte proliferation, but also the pro-
liferation of VSMCs (7), mesangial cells (8) and myofibrob-
lasts (9), suggesting that MPA may have the potential to
prevent and perhaps treat chronic allograft vasculopathy.
The inhibition of de novo guanosine synthesis has been
shown to be the major mechanism, whereby MPA sup-
presses lymphocyte (10,11) and mesangial cell (8) prolifer-
ation. However, the manner in which MPA inhibits VSMC
proliferation has not yet been clearly understood. Cells and
tissues can be arranged in terms of their dependency on
the de novo or salvage pathways involved in guanosine
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synthesis, with lymphocytes at one extreme, brain cells at
the other, and other cells occupying intermediate positions
(12). It is therefore possible that other mechanisms than
IMPDH inhibition may play a significant role in the inhibition
of VSMC proliferation by MPA.
Recently, reactive oxygen species (ROS), especially the
superoxide anion and hydrogen peroxide, have been pro-
posed to be important signaling molecules in many bi-
ological events, including cell proliferation (13–17). ROS
serve as second messengers that activate multiple cellu-
lar signaling proteins and redox-sensitive transcription fac-
tors, which in turn lead to alterations of many genes that
have important functional roles in the biologic behavior of
VSMCs. In fact, hydrogen peroxide has been suggested
to mediate platelet-derived growth factor (PDGF)-induced
VSMC proliferation (18).
The mitogen-activated protein kinase (MAPK) family, which
includes extracellular-regulated protein kinase (ERK), c-jun
N-terminal protein kinase (JNK) and p38 MAPK, is a ubiq-
uitous cellular serine-threonine kinase, which plays a fun-
damental role in a variety of cellular responses to diverse
extracellular stimuli in many different cells (19). In fact, ERK
1/2 mediates PDGF-induced VSMC proliferation and migra-
tion (20). The p38 MAPK was recently found to participate
in VSMC proliferation in response to thrombin and balloon
injury (21,22).
We, therefore, hypothesized that MPA may inhibit PDGF-
induced VSMC proliferation by inhibiting cellular ROS and
subsequent ERK 1/2 and p38 MAPK activation, in addition
to inhibiting de novo guanosine synthesis.
Materials and Methods
Chemicals and instruments
All chemicals and tissue culture plates were obtained from the Sigma Chem-
ical Company (St. Louis, MD, USA) or from Becton Dickinson Labware (Lin-
coln Park, NJ, USA), respectively, unless otherwise stated.
Cell cultures
Rat VSMCs were isolated and characterized as previously described (23).
Briefly, primary cultured rat VSMCs were obtained by the collagenase dis-
sociation of the aortas of Sprague-Dawley rats weighing 200–250 g. Cells
were grown in MEM supplemented with 10% FBS (GIBCO, Grand Island,
NY, USA), 30 mM NaHCO3, 50 mM HEPES, 5 lg/mL insulin, 5 lg/mL trans-
ferrin, 100 U/mL penicillin (GIBCO) and 100 lg/mL streptomycin (GIBCO)
at 37◦C in a 5% CO2 humidified incubator. At confluence, the cells exhib-
ited a characteristic ‘hill and valley’ morphology. Immunocytochemical study
confirmed that the cells stained positively for anti-a1-actin antibody (DAKO
Japan Co., Kyoto, Japan). Passages 5–9 were used in the study.
Drug treatments
Near confluent rat VSMCs were incubated with serum-free MEM for
48 h to arrest and synchronize cell growth. Media were then replaced with
fresh serum-free MEM containing 10 ng/mL of PDGF-BB, and cells were
incubated for up to 48 h. PDGF-BB is the most potent mitogen among
PDGF-AA, -AB and -BB (24). The concentration of PDGF-BB used was de-
termined by preliminary study (data not shown). MPA was administered
1 h before the addition of PDGF. Anti-oxidants [5 mM N-acetylcystein (NAC)
or 500 lM trolox], 50 lM PD98059 (a known MEK, direct ERK 1/2 up-
stream kinase, inhibitor; Calbiochem, San Diego, CA, USA) and 10 lM
p38 MAPK inhibitor [2-(-4-chlorophenyl)-4-(4-fluorophenyl)-5-pyridin-4-yl-1,2-
dihydropyrazol-3-one; Calbiochem], were administered 1 h before PDGF to
determine the roles of ROS, ERK 1/2 and p38 MAPK on PDGF-induced pro-
liferation, respectively. The p38 MAPK inhibitor used in the present study
has been reported to be 8-fold more potent than SB203580 as an inhibitor of
p38 MAPK (25). Guanosine 100 lM with or without MPA was administered
1 h before PDGF to investigate the role of de novo synthesis of guanosine
on PDGF-induced VSMC proliferation.
[3H]-Thymidine incorporation
DNA synthesis was assessed by [3H]-thymidine incorporation. VSMCs were
allowed to proliferate in response to 10 ng/mL of PDGF-BB. One lCi/mL
of [3H]-thymidine (Du Pont Co., Wilmington, DE, USA) was added to each
well for the last 12 h of experimental periods. The cells were then washed
twice and trypsinized before harvesting with a cell harvester (Titertek Cell
Harvester 550, Flow Laboratories, Irvine, Scotland, UK) onto glass-fiber fil-
ters (Flow Laboratories, Irvine, Scotland, UK). They were then placed in a
3 mL scintillation cocktail solution, and their radioactivities were measured
using a b-counter (TL 5000s, Beckman Instruments Inc., Fullerton, CA,
USA).
Flow cytometry
5-(and 6-) chloromethyl-2′,7′-dichlorodihydro-fluorescein diacetate (DCFH-
DA; Molecular Probes, Eugene, OR, USA)-sensitive cellular ROS was mea-
sured by flow cytometry (Becton Dickinson Labware). The cells were
washed twice with cold PBS and incubated with 5 lM DCFH-DA for 20
min. After washing unincorporated dye, fluorescence was determined by
flow cytometry (excitation; 485 nm, emission; 530 nm).
Western blot analysis
ERK1/2 and p38 MAPK activation was measured by Western blot analy-
sis. Briefly, cells were washed with cold PBS and lysed in a lysis buffer
containing 1.0% Triton X-100, 10% glycerol, 20 mM Tris-HCl (pH 7.0),
137 mM sodium chloride, 5 mM EDTA, 20 lM leupeptin, 1 lg/mL apro-
tinin, 1 mM PMSF, 1 mM sodium orthovanadate, 10 mM sodium fluoride,
1 mM EGTA (pH 8.0), 1 mM pyrophosphate and 1 mM b-glycerophosphate.
Insoluble materials were removed by centrifugation at 12000 rpm for
15 min at 4◦C and the concentration of cellular protein was measured using
the Bio-rad protein assay kit (Bio-rad, Hercules, CA, USA). Aliquots contain-
ing 20 lg of protein, for ERK 1/2 determination, and 50 lg of protein for
p38 MAPK determination, were mixed with loading buffer (60 mM Tris-HCl,
25% glycerol, 2% SDS, 14.4 mM 2-ME, 0.1% bromophenol blue), sepa-
rated in a 10% SDS-PAGE and transferred to a nitrocellulose membrane
(Bio-rad). After being blocked for 1 h with 5% non-fat dry milk, the mem-
branes were incubated with anti-ERK 1/2 or anti-p38 MAPK phosphorylated
antibody (Cell Signaling, Beverly, MA, USA). Blots were washed and then in-
cubated with horseradish-peroxidase (HRP)-conjugated anti-rabbit antibody
for 1 h at room temperature. Sites of antibody binding were visualized by us-
ing an enhanced chemiluminescence (ECL; Amersham, Buckinghamshire,
UK) Western blotting detection system, and quantified using a densitome-
ter. All ERK and p38 MAPK measurements were normalized versus total
ERK 1/2 or total p38 MAPK, which were reprobed using the respective
specific antibodies (cell signaling).
Statistical analysis
All results were calculated by relative ratio against control (without any
agent), and were expressed as means ± SE. The mean values obtained from
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Figure 1: MPA inhibited PDGF-
induced rat VSMC proliferation at
48 h and exogenous guanosine par-
tially overcame the inhibition of
MPA. Cell proliferation was measured
by [3H]-thymidine incorporation after
exposing quiescent VSMCs to serum-
free media containing different con-
centrations of MPA, in the presence
or absence of 100 lM guanosine,
which were added before the addition
of 10 ng/mL of PDGF-BB. The experi-
mental protocol is detailed in the ‘Ma-
terials and Methods’ section. Data are
presented as means ± SE of five ex-
periments. ∗p < 0.05 versus control.
†p < 0.05 versus PDGF without MPA.
each group were compared by ANOVA and subsequently using Fisher’s
least significance difference method. p-Values of <0.05 were accepted for
statistical significance.
Results
MPA inhibited PDGF-induced rat VSMC proliferation
[3H]-thymidine incorporation was measured after 48 h in
the presence or absence of PDGF at 10 ng/mL. PDGF
increased [3H]-thymidine incorporation by 3.4-fold (from
397.0 ± 51.7 cpm basal value to 1367.3 ± 327.2 cpm)
that of the control (Figure 1, p < 0.05, n = 5). MPA at
concentrations higher than 100 nM significantly inhibited
PDGF-induced [3H]-thymidine up-regulation (Figure 1, p <
0.05, n = 5). The IC50 of MPA was between 100 nM and
1 lM.
Exogenous guanosine 100 lM did not affect basal [3H]-
thymidine incorporation but partially overcame the inhibi-
tion of MPA on PDGF-induced [3H]-thymidine incorporation
(Figure 1, p < 0.05, n = 5). [3H]-thymidine incorporation of
VSMCs in the presence of PDGF, MPA 10 lM and guano-
sine 100 lM was 2.4-fold (957.4 ± 115.6 cpm) that of the
control. This was significantly higher than PDGF and MPA
10 lM, but still lower than PDGF alone.
MPA inhibited PDGF-induced cellular ROS
in rat VSMCs
PDGF at a concentration that induced cell proliferation,
rapidly (at 5 min) increased cellular ROS by 1.6-fold that
of the control (Figure 2A, p < 0.05, n = 5). MPA at above
10 nM inhibited PDGF-induced cellular ROS in a dose-
dependent manner (Figure 2B, p < 0.05, n = 5). Cellular
ROS in VSMCs cultured under PDGF and 10 lM of MPA
was 1.1-fold that of the control.
MPA inhibited PDGF-induced ERK 1/2 and p38 MAPK
activation in rat VSMCs
PDGF at a concentration that induced cell proliferation also
increased both ERK 1/2 and p38 MAPK activation (Figure
3). PDGF-induced ERK 1/2 activation peaked at 15 min by
3.3-fold that of the control (p < 0.05, n = 4). PDGF-induced
p38 MPAK activation at 5 min was 3.9-fold higher than
control (p < 0.05, n = 4).
MPA at above 1 lM significantly reduced PDGF-induced
ERK 1/2 (Figure 4A, B, p < 0.05, n = 4) and p38 MAPK acti-
vation (Figure 4A, C, p < 0.05, n = 4) in a dose-dependent
manner. ERK 1/2 and p38 MAPK activation in the presence
of PDGF and MPA 10 lM were 2.4-fold and 2.4-fold that
of the control, respectively. However, ERK 1/2 activation
remained statistically higher than control.
Cellular ROS generation and the activation of ERK 1/2
and p38 MAPK are required for the PDGF-induced
proliferation of rat VSMCs
Structurally different anti-oxidants (NAC 5 mM or trolox
500 lM), the ERK inhibitor (PD98059 50 lM) and the p38
MAPK inhibitor (p38 I 10 lM) all effectively inhibited PDGF-
induced [3H]-thymidine up-regulation (Figure 5, p < 0.05,
n = 5). The anti-oxidants also inhibited PDGF-induced ERK
1/2 (Figure 6A, B, p < 0.05, n = 5) and p38 MAPK activation
(Figure 6A, C, p < 0.05, n = 5), suggesting that ERK 1/2
and p38 MAPK activation are downstream molecules of
cellular ROS in VSMCs cultured under PDGF.
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Figure 2: MPA inhibited PDGF-
induced cellular ROS generation
in rat VSMCs. (A) Time course of
PDGF-induced cellular ROS genera-
tion. (B) Effects of MPA on PDGF-
induced cellular ROS generation at
5 min. The experimental protocol is
detailed in the ‘Materials and Meth-
ods’ section. Data are presented as
means ± SE of five experiments.
∗p < 0.05 versus control. †p < 0.05
versus MPA 0.
Figure 3: PDGF increased ERK 1/2
and p38 MAPK activation in rat
VSMCs. The experimental protocol is
detailed in the ‘Materials and Meth-
ods’ section. Data are presented as
representative Western blot pictures
of five experiments.
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Figure 4: MPA inhibited PDGF-
induced ERK 1/2 and p38 MAPK ac-
tivation in rat VSMCs. (A) Represen-
tative Western blot analysis of ERK
1/2 and p38 MAPK activation. Each
protein band was quantified by densit-
ometry. (B) Effects of MPA on PDGF-
induced ERK1/2 activation. (C) Effects
of MPA on PDGF-induced p38 MAPK
activation. The experimental protocol
is detailed in the ‘Materials and Meth-
ods’ section. Data are presented as
means ± SE of four experiments,
∗p < 0.05 versus MPA 0 without
PDGF. †p < 0.05 versus PDGF with-
out MPA.
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Figure 5: ROS, ERK and p38
MAPK are required for the
PDGF-induced proliferation of rat
VSMCs. Proliferation was measured
by determining [3H]-thymidine incor-
poration after exposing quiescent
VSMCs to serum free media con-
taining NAC, trolox, PD98059 and
p38 MAPK inhibitor (p38 inhibitor),
which were added 1 h before the
addition of PDGF 10 ng/mL. The
experimental protocol is detailed in
the ‘Materials and Methods’ section.
Data shown are the means ± SE of
five experiments. ∗p < 0.05 versus
control without PDGF. †p < 0.05
versus PDGF control.
Discussion
In this study, we observed that; (1) PDGF increased pro-
liferation, cellular ROS and the activation of ERK 1/2 and
p38 MAPK in VSMCs; (2) MPA at concentrations inhibiting
PDGF-induced VSMC proliferation blocked PDGF-induced
cellular ROS, and partially but significantly inhibited the
activation of ERK 1/2 and p38 MAPK; (3) Structurally dif-
ferent anti-oxidants, ERK 1/2 inhibitor and p38 MAPK in-
hibitor blocked PDGF-induced VSMC proliferation; (4) The
anti-oxidants also blocked PDGF-induced ERK 1/2 and
p38 MAPK in cultured VSMCs; and finally, (5) Exogenous
guanosine partially overcame the anti-proliferative effect
of MPA. These observations suggest that MPA may inhibit
PDGF-induced VSMC proliferation partially through inhibit-
ing cellular ROS and subsequent ERK 1/2 and p38 MAPK
activation, in addition to inhibiting de novo guanosine
synthesis.
The present observation that treatment with PDGF at
10 ng/mL for 48 h increased rat VSMC proliferation con-
firmed the findings of our previous study (7). MPA effec-
tively inhibited PDGF-induced VSMC proliferation in a dose-
dependent manner (0.1–10 lM) at 48 h. In the present
study, the IC50 of MPA for the PDGF-induced DNA syn-
thesis in VSMCs was 100 nM to1 lM, which agrees with
the findings of Mohacsi et al (26). Clinically attainable con-
centrations of MPA (1–10 lM) were reported to inhibit the
human arterial smooth muscle cell and fibroblast prolifera-
tion in culture (12).
MPA inhibited PDGF-induced cellular ROS in a dose-
dependent manner. The quantification of PDGF-induced
ROS by flow cytometry in the present study agrees with
a previous report by Sundarasen et al. (18), in which ROS
was quantified by confocal microscopy. While the mech-
anisms involved in the inhibition of cellular ROS by MPA
are not clear at present, PDGF increases cellular ROS
through NAD(P)H oxidase through Gi1,2 and Ras family
proteins (27,28). PDGF activates heterotrimeric G-proteins
or small G-proteins, such as Rac, Ras and Rho (29). Tiazo-
furin, another IMPDH inhibitor, down-regulated the expres-
sion of heterotrimeric G-protein or small G-protein (30–32).
The effects of MPA on the PDGF-induced heterotrimeric
G-proteins or small G-proteins need to be addressed in
future studies. In the present study, MPA inhibited PDGF-
induced cellular ROS at a 100-fold lower concentration than
that required with inhibiting cell proliferation. This suggests
that an anti-oxidative effect of MPA may be necessary but
not sufficient to inhibit VSMC proliferation. To the best of
our knowledge, the inhibitory effect of MPA on cellular ROS
generation has not been previously reported.
PDGF significantly increased ERK 1/2 activation, and MPA
inhibited PDGF-induced ERK 1/2 activation in a dose-
dependent manner. MPA at above 1 lM significantly in-
hibited ERK 1/2 activation. The observation that PD98059
effectively inhibited VSMC proliferation, suggests that the
inhibitory effect of MPA on PDGF-induced VSMC prolifer-
ation may be due to the inhibition of ERK 1/2 activation.
However, the inhibition of ERK 1/2 activation by MPA re-
mained significantly higher than control (Figure 4A, B) at
the face of total blockade of proliferation. This result sug-
gests that there may be threshold for the activation of ERK
1/2 involved in PDGF-induced VSMC proliferation.
PDGF was found to significantly increase p38 MAPK acti-
vation, and MPA blocked p38 MAPK activation at concen-
trations above 1 lM (Figure 4A, C). The finding that p38
MAPK inhibitor, a selective inhibitor of p38 MAPK, inhib-
ited PDGF-induced proliferation, suggests that p38 MAPK
may also play an important role in PDGF-induced VSMC
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Figure 6: ROS mediates PDGF-
induced ERK 1/2 and p38 MAPK
activation. (A) Representative West-
ern blot analysis of ERK 1/2 and p38
MAPK activation. Each protein band
was quantified by densitometry. (B)
Effects of NAC and trolox on PDGF-
induced ERK 1/2 activation. (C) Effects
of NAC and trolox on PDGF-induced
p38 MAPK activation. The experimen-
tal protocol is detailed in the ‘Mate-
rials and Methods’ section. Data are
the means ± SE of five experiments.
∗p < 0.05 versus control without
PDGF. †p < 0.05 versus PDGF control.
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proliferation. The role of p38 MAPK in the proliferation of
VSMCs has recently been suggested in thrombin-induced
VSMC proliferation (21) and balloon injury-induced neointi-
mal hyperplasia (22).
Effects of anti-oxidants on PDGF-induced ERK 1/2 and p38
MAPK activation suggest that ERK 1/2 and p38 MAPK ac-
tivation are downstream of ROS in VSMCs cultured in the
presence of PDGF.
We further tested whether guanosine restores the in-
hibitory effect of MPA on rat VSMC proliferation, since that
anti-proliferative effect of MPA is dependent on the inhibi-
tion of IMPDH in lymphocytes (10,11), and that MPA effec-
tively decreased mesangial cell proliferation by guanosine
depletion (8). Exogenous guanosine partially overcame the
inhibition of MPA on PDGF-induced cell proliferation sug-
gesting that the inhibition of IMPDH may play a role in
anti-proliferative effect of MPA on VSMC proliferation but
not be the sole mechanism.
In conclusion, our findings suggest that MPA may inhibit
PDGF-induced rat VSMC proliferation partly through inhibit-
ing cellular ROS and subsequent ERK 1/2 and p38 MAPK
activation in addition to inhibiting de novo guanosine syn-
thesis. The relative importance of these effects of MPA
on PDGF-induced signaling molecules and guanosine de-
pletion on the inhibition of VSMC proliferation remains an
issue for further study.
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